Lv1
20 积分 2025-11-03 加入
Rational design of TGFbRII dominant negative armored GPC3 CAR-T cells for the treatment of hepatocellular carcinoma
21天前
已完结
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β
2个月前
已完结
In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor
3个月前
已完结
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
4个月前
已完结
Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T‐Cell Engager, in Prostate Cancer Patients
4个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
5个月前
已完结
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
5个月前
已完结
Epitope Mapping for a Preclinical Bevacizumab (Avastin) Biosimilar on an Extended Construct of Vascular Endothelial Growth Factor A Using Millisecond Hydrogen–Deuterium Exchange Mass Spectrometry
5个月前
已完结
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
5个月前
已完结
Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy
5个月前
已完结
皖公网安备34019202002308
